Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1997-3-31
|
pubmed:abstractText |
Interferon a (IFN) is the only agent currently approved by the FDA for the treatment of chronic viral hepatitis due to hepatitis C (HCV). Unfortunately, less than half the patients with HCV treated with IFN respond. Worse yet, half or more of those who do respond relapse when the agent is withdrawn.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0172-6390
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
43
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1557-61
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8975965-Female,
pubmed-meshheading:8975965-Hepatitis C,
pubmed-meshheading:8975965-Humans,
pubmed-meshheading:8975965-Interferon-alpha,
pubmed-meshheading:8975965-Male,
pubmed-meshheading:8975965-Middle Aged,
pubmed-meshheading:8975965-Phlebotomy,
pubmed-meshheading:8975965-Treatment Failure,
pubmed-meshheading:8975965-Treatment Outcome
|
pubmed:articleTitle |
Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy.
|
pubmed:affiliation |
Oklahoma Transplant Institute, Baptist Medical Center of Oklahoma, Oklahoma City 73112, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|